A federal appeals court on Thursday ordered a new trial in a high-profile patent infringement dispute over Sanofi’s drug Praluent and lifted a  permanent injunction barring sales of the biologic, used to fight high cholesterol.

Judge Sharon Prost of the U.S. Court of Appeals for the Federal Circuit found that a Delaware federal judge improperly excluded evidence from Sanofi and its development partner Regeneron Pharmaceuticals Inc. in the case and relayed incorrect instructions to a jury, which last year upheld the validity of Amgen Inc.’s patents on a competing biologic, Repatha.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]